Betterlife Pharma

Name

Betterlife Pharma

Legal name

BetterLife Pharma Inc.

Website

https://abetterlifepharma.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Psychedelic pharmaceuticals
• Neurological disorder treatments
• Biotech drug development
• Neuro-psychiatric therapies
• Clinical stage biotechnology

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue biotech company focused on developing and commercializing patient-friendly compounds to treat neuro-psychiatric and neurological disorders. Revenue expected upon regulatory approval and commercialization of BETR-001 and other pipeline compounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BetterLife Pharma is a clinical-stage biotechnology company developing BETR-001 (2-Bromo-LSD), a non-hallucinogenic second-generation LSD derivative for treating neuro-psychiatric and neurological disorders including treatment-resistant depression, PTSD, anxiety, and chronic cluster headaches. The company is advancing BETR-001 through IND-enabling studies toward a Q1 2027 FDA IND filing and Phase 1 clinical trials. Additional pipeline assets include BETR-002 for neuro-psychiatric disorders and AP-003 (recombinant interferon alpha-2b) for COVID-19.

Product overview

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. The company's lead pipeline consists of BETR-001 (2-Bromo-LSD), a non-hallucinogenic LSD derivative being developed for treatment-resistant depression, PTSD, and cluster headaches; BETR-002 for neuro-psychiatric disorders; and AP-003 (rhIFNα2b), an interferon-based therapy that completed Phase 1/2 COVID-19 trials. The company also worked on TD-0148A (which is the same compound as BETR-001) and TD-010 for anxiolytic-use disorder. BetterLife operates as a pure biotech with no software products or platform offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• BETR-001 (2-Bromo-LSD) Lead product candidate — a second-generation non-hallucinogenic LSD derivative molecule being developed for treating neuro-psychiatric and neurological disorders including treatment-resistant depression, PTSD, anxiety, and chronic cluster headaches. Mimics projected therapeutic properties of LSD without hallucinogenic side effects and is patient self-administered.
• BETR-002 Biotech compound being developed for neuro-psychiatric disorders alongside BETR-001 as part of BetterLife Pharma's psychedelic derivative pipeline.
• AP-003 (rhIFNα2b) Recombinant interferon alpha-2b product that completed Phase 1 and initiated Phase 2 clinical trials for COVID-19 treatment in Chile, conducted with Pontificia Universidad Católica de Chile.

Quantifiable outcome

• Demonstrated anti-depressant activity in preclinical models of depression
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, minor and supporting.

• Syner-G BioPharma GroupcoreStrategic or Co-development Partner · 25 June 2026BetterLife Pharma engaged Syner-G BioPharma Group to oversee GMP manufacturing of BETR-001. Syner-G provides CMC and regulatory expertise to support the company's path to first-in-human clinical studies and IND filing.
• GTM StudiosminorGTM or Marketing Partner · 25 June 2026BetterLife engaged Vancouver-based GTM Studios for two months of marketing material production at $4,000 per month.
• YAFO CapitalcoreStrategic or Co-development Partner · 11 December 2025BetterLife Pharma engaged Shanghai-based YAFO Capital to seek strategic partnerships for developing BETR-001 in Greater China. YAFO will leverage its network to facilitate development and partnerships in Asia.
• Daniel CarcillosupportingOthers · 3 April 2025Former NHL player Daniel Carcillo appointed as Corporate Advisor, bringing patient advocacy perspective for traumatic brain injury and mental health.
• Medical College WisconsinsupportingStrategic or Co-development Partner · 9 September 2021BetterLife entered research agreement with Medical College Wisconsin for TD-0148A neurological receptor studies.
• Dr. Thomas LaughrensupportingOthers · 8 April 2021Former FDA Psychiatry Division Director Dr. Thomas Laughren joined BetterLife as Regulatory Advisor, providing guidance on FDA regulatory pathway for BETR-001.
• University of California San Diego (UCSD)supportingStrategic or Co-development Partner · 24 March 2021BetterLife entered research agreement with UCSD for TD-0148A behavioural pharmacology studies, working with researchers including Adam Halberstadt.
• Carleton UniversitysupportingStrategic or Co-development Partner · 8 March 2021BetterLife entered research agreement with Carleton University for TD-0148A depression studies. The collaboration has received Mitacs Accelerate funding for chronic anxiety and depression research.
• Eurofins CDMO (Alphora)supportingStrategic or Co-development Partner · 3 March 2021BetterLife engaged Eurofins CDMO for next generation psychedelic TD-0148A manufacturing.
• Eurofins DiscoverysupportingStrategic or Co-development Partner · 28 January 2021BetterLife engaged Eurofins Discovery for next generation psychedelics 2-bromo-LSD FDA IND-enabling pharmacology studies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• atai Life Sciences: atai Life Sciences is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health. It operates a portfolio approach similar in spirit to BetterLife's multi-indication CNS strategy.
• GH Research PLC: GH Research is a clinical-stage biopharmaceutical company developing mebufotenin and other tryptamine-based therapies for treatment-resistant depression. It targets the same patient population as BETR-001 with a similarly differentiated psychedelic mechanism.
• Bright Minds Biosciences: Bright Minds Biosciences is a clinical-stage biotech developing novel serotonergic compounds (including 5-HT2C and 5-HT2A agonists) for epilepsy and CNS disorders. It is a direct psychedelic-adjacent CNS peer with similar mechanism-based differentiation.
• Cybin Inc. Cybin is a clinical-stage psychedelic CNS biotech developing psilocybin analogs and deuterated tryptamines for depression and other neuropsychiatric indications. It is the most directly comparable psychedelic CNS peer, and former Cybin CEO Doug Drysdale now chairs BetterLife.
• Mind Medicine (MindMed) Inc. MindMed is a clinical-stage psychedelic biotech developing LSD-based therapies (including an LSD neutralizer) and other neuropsychiatric candidates. It directly competes with BetterLife in LSD-derivative neuropsychiatric development and shares the same psychedelic CNS therapeutic thesis.
• Compass Pathways plc: Compass Pathways is a mental health care company developing psilocybin therapy for treatment-resistant depression. It is a direct competitor in psychedelic-based depression treatment and the most advanced clinical peer in this indication.

Emerging players

• Lobe Sciences: Lobe Sciences is an emerging biotech developing psychedelic-inspired therapeutics for neurological and mental health conditions. It is a smaller-scale comparator pursuing adjacent neuropsychiatric indications to BetterLife.
• Field Trip Health & Therapeutics: Field Trip operates psychedelic-assisted therapy clinics and is developing next-generation psychedelic compounds. It overlaps with BetterLife's neuropsychiatric focus through both drug development and the patient funnel for psychedelic mental health treatment.

Broad incumbents

• Eli Lilly (Lilly Neuroscience): Lilly is a global pharmaceutical incumbent with a major CNS and depression franchise (Cymbalta, Zepbound adjacencies). It represents the strategic-partner or acquirer profile that BetterLife's BETR-001 could attract if clinical data de-risks the asset.
• Psilocybin/SSRI-class developers (e.g., Sage Therapeutics): Sage Therapeutics develops CNS-targeted therapies for depression and neurological disorders (e.g., Zurzuvae for postpartum depression). It is a broader incumbent CNS player whose indications overlap with BETR-001's target markets and provides a benchmark for CNS drug commercialisation economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks1 record

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCg6ZzyqVhqv5J-8q-J4xGQQ
• LinkedInlinkedin.com/company/betterlife-pharma
• Facebookfacebook.com/BetterLifePharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds13 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Betterlife Pharma